FNDX vs XBI
Schwab Fundamental US Large Company Index ETF vs SPDR S&P Biotech ETF
- • FNDX has the lower expense ratio at 0.25% vs 0.35% for XBI.
- • FNDX pays a higher dividend yield (1.44%).
Side-by-side metrics
| Metric | FNDX | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.25% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.44% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $28.47B | $10.92B |
YTD return | 21.76% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.78 | 1.01 |
P/E ratio | 19.05 | — |
Last price | $32.96 | $156.41 |
Inception | — | — |
Issuer | Schwab | State Street |
FNDX top holdings
| AAPL | Apple Inc | 4.84% |
| MSFT | Microsoft Corp | 3.14% |
| XOM | ExxonMobil Holdings Corp | 2.63% |
| BRK-B | Berkshire Hathaway Inc Class B | 1.83% |
| AMZN | Amazon.com Inc | 1.80% |
| CVX | Chevron Corp | 1.77% |
| JPM | JPMorgan Chase & Co | 1.55% |
| META | Meta Platforms Inc Class A | 1.51% |
| UNH | UnitedHealth Group Inc | 1.44% |
| GOOGL | Alphabet Inc Class A | 1.40% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About FNDX
FNDX (Schwab Fundamental US Large Company Index ETF) is US large caps weighted by fundamental factors. Managed by Schwab, the fund carries $28.5B in assets under management, an expense ratio of 0.25%, a dividend yield of 1.44%. Its largest holding is Apple Inc (AAPL), which represents 4.8% of the portfolio. Real Estate is the fund's largest sector exposure at 1.8%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.